RhumbLine Advisers’s Tourmaline Bio TRML Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2025
Q4 | – | Sell |
-27,057
| Closed | -$1.29M | – | 4177 |
|
|
2025
Q3 | $1.29M | Sell |
27,057
-2,959
| -10% | -$82.1K | ﹤0.01% | 2115 |
|
|
2025
Q2 | $480K | Sell |
30,016
-3,017
| -9% | -$48.9K | ﹤0.01% | 2706 |
|
|
2025
Q1 | $502K | Sell |
33,033
-2,558
| -7% | -$41K | ﹤0.01% | 2575 |
|
|
2024
Q4 | $722K | Buy |
35,591
+718
| +2% | +$18.1K | ﹤0.01% | 2433 |
|
|
2024
Q3 | $897K | Buy |
34,873
+1,634
| +5% | +$27.3K | ﹤0.01% | 2319 |
|
|
2024
Q2 | $427K | Buy |
33,239
+33,123
| +28,554% | +$533K | ﹤0.01% | 2782 |
|
|
2024
Q1 | $2.66K | Hold |
116
| – | – | ﹤0.01% | 4061 |
|
|
2023
Q4 | $3.04K | Hold |
116
| – | – | ﹤0.01% | 4053 |
|
|
2023
Q3 | $3.27K | Sell |
116
-234
| -67% | -$6.85K | ﹤0.01% | 4042 |
|
|
2023
Q2 | $10.6K | Sell |
350
-3,092
| -90% | -$78.9K | ﹤0.01% | 3936 |
|
|
2023
Q1 | $65K | Buy |
3,442
+20
| +0.6% | +$330 | ﹤0.01% | 2895 |
|
|
2022
Q4 | $35K | Buy |
3,422
+57
| +2% | +$916 | ﹤0.01% | 2969 |
|
|
2022
Q3 | $88K | Buy |
3,365
+194
| +6% | +$7.07K | ﹤0.01% | 3014 |
|
|
2022
Q2 | $143K | Buy |
3,171
+1,677
| +112% | +$132K | ﹤0.01% | 2999 |
|
|
2022
Q1 | $147K | Buy |
1,494
+64
| +4% | +$5.99K | ﹤0.01% | 2824 |
|
|
2021
Q4 | $219K | Buy |
+1,430
| New | +$212K | ﹤0.01% | 2810 |
|
RhumbLine Advisers's TRML Position: Q4 2025 in Review
RhumbLine Advisers sold out of Tourmaline Bio (TRML) in Q4 2025, closing a stake of 27,057 shares — an estimated $1.29M sold.
RhumbLine Advisers first reported a position in TRML in Q4 2021 and held it in 16 quarters. The position peaked at $1.29M in Q3 2025. 0 funds tracked by Wall St. Rank hold TRML as of Q4 2025.
- RhumbLine Advisers reported no remaining Tourmaline Bio position as of Q4 2025 after selling out during the quarter.
- RhumbLine Advisers sold 27,057 Tourmaline Bio shares in Q4 2025, an estimated $1.29M.
- RhumbLine Advisers first reported a position in Tourmaline Bio in Q4 2021 and held it in 16 quarters.
- RhumbLine Advisers's Tourmaline Bio position peaked at $1.29M in Q3 2025.
- 0 funds tracked by Wall St. Rank held Tourmaline Bio as of Q4 2025.
Based on RhumbLine Advisers's 13F filing for Q4 2025, filed 13 Feb 2026.